Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 7/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313667 | 0.88 | MEN1 (0.36) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10275937 | 0.86 | LDHA (0.40) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10275476 | 0.86 | ALOX5AP (0.34) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10275664 | 0.85 | ADORA1 (0.40) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10313668 | 0.85 | MAPK14 (0.32) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10313670 | 0.85 | MAPK14 (0.34) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10275347 | 0.85 | ADORA1 (0.40) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10276174 | 0.83 | ABCC8 (0.38) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10313660 | 0.78 | ALDH1A1 (0.38) | MAPK13MAPK12MAPK11MAPK14KCNH2 | |
| SCHEMBL10313656 | 0.75 | ALDH1A1 (0.44) | MAPK13MAPK12MAPK11MAPK14KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | MAPK13 1195/4885MAPK12 2155/4885MAPK11 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.